Actively Recruiting
Observational Study Evaluating Long-Term Safety of Odevixibat in Patients with Alagille Syndrome
Led by Ipsen · Updated on 2026-10-23
30
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing the long-term safety of odevixibat in patients with Alagille Syndrome ALGS, a rare liver disease that causes itching. This observational study collects information from patients who are already using odevixibat in their daily lives to better understand the medications safety over time. Participants are those with ALGS who are receiving ongoing treatment with odevixibat. The study does not involve assigning treatments but monitors the participants as they continue their prescribed medication. Data is collected over approximately five years to assess safety and related health outcomes. During the study, participants health is monitored through records of adverse events, serious adverse events, diarrhoea occurrences, vitamin levels, liver function tests, hospitalizations, and treatment changes. This long-term observation aims to provide a comprehensive picture of odevixibats safety profile in real-world use, with total participation lasting about five years.
CONDITIONS
Brief Title
A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Research Team
I
Ipsen Clinical Study Enquiries
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here